Two-day therapy with cefuroxime axetil is effective for urinary tract infections in children.
Short-course therapy for pediatric urinary tract infection (UTI) remains controversial. The present study was undertaken to compare the effectiveness of cefuroxime axetil (Ceftin) as short-course (2-day) versus conventional (10-day) therapy for uncomplicated pediatric UTIs. In a randomized, controlled, prospective study, we enrolled 50 children, 2-11 years of age, to receive oral cefuroxime axetil, 125 mg twice a day, for either 2 or 10 days. UTI was defined as at least 10(5) colonies/ml of a single pathogen isolated on clean catch, or at least 10(4) colonies/ml on a catheterized specimen. A 10-fold or greater reduction in colony count of the initially isolated organism (3-5) days after stopping therapy was considered a bacteriologic success, as long as the absolute colony count was below the threshold for UTI described above. Patients were followed for 15 months with multiple repeat urine cultures and radiologic studies. Twenty-five of the 50 patients enrolled were withdrawn, including 12 for initially inadequate colony counts. Eight of 12 patients in the short-course group (67%), versus 12 of 14 in the conventional-therapy group (86%), were initial bacteriological successes, a nonsignificant difference. All 37 initially isolated uropathogens were sensitive to cefuroxime axetil in vitro. Cefuroxime axetil is an effective antimicrobial for uncomplicated pediatric UTIs. Two-day therapy with cefuroxime axetil appears to be as effective as 10-day therapy, although sample size was limited in this study.
Department of Pediatrics, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Children's Hospital of Buffalo 14222.
A E
AE
Kornberg
K
K
Sherin
P
P
Veiga
P K
PK
Mydlow
J J
JJ
Collins
L G
LG
Feld
D000284:Administration, Oral; D002444:Cefuroxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D015169:Colony Count, Microbial; D004334:Drug Administration Schedule; D004926:Escherichia coli / Q000254:growth & development; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011355:Prodrugs / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies; D013997:Time Factors; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D011355:Prodrugs; D002444:Cefuroxime; C040738:cefuroxime axetil